EUVIMEDEUVIMED entdecken
Crossref

Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Frédéric Baron iD, Myriam Labopin, Jurjen Versluis, Jan Vydra, Peter A von dem Borne, Emma Nicholson iD, Didier Blaise, Rachel Protheroe, Alexander Kulagin iD, Claude Eric Bulabois, Montserrat Rovira, Patrice Chevallier iD und 6 weitere

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Frédéric Baron und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium. Hauptthemen laut MEDLINE: Graft vs Host Disease, Leukemia, Myeloid, Acute, Cyclophosphamide, Unrelated Donors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Fonds De La Recherche Scientifique - FNRS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The best donor option for acute myeloid leukemia (AML) patients lacking an HLA‐matched donor has remained intensively debated. We herein report the results of a large retrospective registry study comparing hematopoietic cell transplantation (HCT) outcomes between double‐unit umbilical cord blood transplantation (dCBT, n = 209) versus 9/10 HLA‐matched unrelated donor (UD) with posttransplant cyclophosphamide (PTCy)‐based graft‐versus‐host disease (GVHD) prophylaxis (UD 9/10, n = 270) in patients with AML in first complete remission (CR1). Inclusion criteria consisted of adult patient, AML in CR1 at transplantation, either peripheral blood stem cells (PBSC) from UD 9/10 with PTCy as GVHD prophylaxis or dCBT without PTCy, transplantation between 2013 and 2021, and no in vivo T‐cell depletion. The 180‐day cumulative incidence of grade II‐IV acute GVHD was 29% in UD 9/10 versus 44% in dCBT recipients ( p = .001). After adjustment for covariates, dCBT recipients had a higher non‐relapse mortality (HR = 2.35, 95% CI: 1.23–4.48; p = .01), comparable relapse incidence (HR = 1.12, 95% CI: 0.67–1.86; p = .66), lower leukemia‐free survival (HR = 1.5, 95% CI: 1.01–2.23; p = .047), and lower overall survival (HR = 1.66, 95% CI: 1.08–2.55; p = .02) compared with patients receiving UD 9/10 HCT. In summary, our results suggest that transplantation outcomes are better with UD 9/10 with PTCy‐based GVHD prophylaxis than with dCBT for AML patients in CR1. These data might support the use of UD 9/10 with PTCy‐based GVHD prophylaxis over dCBT in AML patients lacking an HLA‐matched donor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseLeukemia, Myeloid, AcuteCyclophosphamideUnrelated DonorsCord Blood Stem Cell TransplantationHumansMiddle AgedMaleFemaleAdultRetrospective StudiesAgedRemission InductionAdolescentYoung AdultRegistriesHematopoietic Stem Cell Transplantation

Substanzen

Cyclophosphamide

Autor:innen und Institutionen

  • Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium.
  • EBMT Paris Study Unit, Paris, France.
  • Clinical Hematology and Cellular Therapy Department, Saint Antoine Hospital, Paris, France.
  • INSERM UMRs 938, Paris, France.
  • Sorbonne University, Paris, France.
  • Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.

ORCID-Profile: Frédéric Baron, Emma Nicholson, Alexander Kulagin, Patrice Chevallier, Annalisa Ruggeri

Förderung

  • Fonds De La Recherche Scientifique - FNRS

Zitieren

APA

Baron, F., Labopin, M., Versluis, J., Vydra, J., von dem Borne, P. A., Nicholson, E., Blaise, D., Protheroe, R., Kulagin, A., Bulabois, C. E., Rovira, M., Chevallier, P., Forcade, E., Byrne, J., Sanz, J., Ruggeri, A., Mohty, M., & Ciceri, F. (2024). Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology. https://doi.org/10.1002/ajh.27466

Vancouver

Baron F, Labopin M, Versluis J, Vydra J, von dem Borne PA, Nicholson E, et al. Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology. 2024. doi:10.1002/ajh.27466

BibTeX
@article{Baron2024,
  author = {Baron, Frédéric and Labopin, Myriam and Versluis, Jurjen and Vydra, Jan and von dem Borne, Peter A and Nicholson, Emma and Blaise, Didier and Protheroe, Rachel and Kulagin, Alexander and Bulabois, Claude Eric and Rovira, Montserrat and Chevallier, Patrice and Forcade, Edouard and Byrne, Jenny and Sanz, Jaime and Ruggeri, Annalisa and Mohty, Mohamad and Ciceri, Fabio},
  title = {Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27466}
}
Kostenlos starten →